The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...
FDA proposals include ‘major updates’ to simplify biosimilarity studies, reduce unnecessary clinical testing, and ease the process for making biosimilars interchangeable with brand-name biologics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback